10-Q quarterly report · filed Nov 9, 2026

Maze Therapeutics, Inc. (MAZE) Q3 2026 10-Q Quarterly Report

Short answer

Maze Therapeutics, Inc. (MAZE) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$48M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$48M
−59.4% YoY · −7.2% QoQ
EPS (diluted)
−$0.80
−29.0% YoY · −3.9% QoQ

Source: XBRL data from the Maze Therapeutics, Inc. (MAZE) Q3 2026 10-Q on SEC EDGAR. USD.

Maze Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY; nine-month license revenue $20.0M vs $0
  • Operating margin -107.3% vs -112.9% YoY, based on operating losses of $51.5M and $33.0M
  • MZE829 R&D spending $7.1M, MZE782 $5.6M, up $2.8M and $3.5M YoY
  • Cash, equivalents and marketable securities $477.0M; operating cash use $87.0M for nine months
  • Outlook: additional capital needed; MZE782 PKU data expected 2027 and MZE829 pivotal trial planned first half 2027

Risk Factors

  • Newly emphasized supply-chain risk: BIOSECURE Act signed December 2025 could restrict WuXi relationships if designated a biotechnology company of concern
  • Regulatory risk: CMS GLOBE model begins January 1, 2027, potentially requiring incremental Medicare Part B rebates tied to international prices
  • Clinical risk: MZE782 Phase 2 PKU trial initiated August 2026, with topline data expected in 2027
  • Operational risk: MZE829 pivotal trial planned first half of 2027, subject to regulatory feedback
  • Financial risk: $477.0 million cash, cash equivalents and marketable securities expected to fund operations for at least one year

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Maze Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.